BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, announces the closing of its fourth fund, BGV IV, at €105 million ($119 million). Strong market interest expediated the fund raise, with the commitments to date exceeding the fund’s original target.
The BGV IV fund has attracted notable institutions as investors such as, Bristol Myers Squibb, Schroder Adveq and the European Investment Fund. New investors to BGV IV include Industriens Pension and KfW Capital.
BGV is one of the largest VC funds in Europe focused on early investments in new bio-technology companies, with over € 220 million assets under management. Its team has broad experience in investment, life sciences, business development, and commercial operations. It also draws on experienced biotech entrepreneurs as venture partners and advisors, to the benefit of its portfolio companies.
The Company’s approach is to partner with scientists from major European institutions and entrepreneurs. The aim is to build new companies, around either single assets or technology platforms with the goal of creating transformational new medicines. This strategy is supported by the strong collaboration between BGV and Forbion, providing a platform across early- to late-stage companies.
Source: BioGeneration Ventures
Can’t stop reading? Read more
Thoma Bravo’s SailPoint targets $11.5bn valuation in US IPO
Cybersecurity firm SailPoint is preparing to go public again in the US, targeting a valuation of...
Balbec Capital closes sixth credit fund at $1.7bn, marking record fundraise
Balbec Capital closed its latest credit fund, Insolve Global Credit Fund VI, securing over $1.7bn...
The saga continues: Brookfield enters $1.9bn bidding war for Insignia Financial
Brookfield Asset Management joined Bain Capital and CC Capital in the race to acquire Insignia...